Pfizer announces deal with Canada for experimental COVID-19 vaccine


Recasts first paragraph with Pfizer announcement

OTTAWA, Aug 5 (Reuters) - Pharmaceutical giant Pfizer Inc PFE.N and German biotech firm BioNTech SE 22UAy.F on Wednesday said they had signed a deal to supply Canada with an experimental coronavirus vaccine.

Deliveries of the BNT162 mRNA-based vaccine candidate are planned over the course of 2021, subject to clinical success and Health Canada approval, the two companies said in a statement. They did not reveal financial details.

Separately, the Canadian government said it would make an announcement on the next steps in procuring vaccines at 10 a.m. ET (1400 GMT) on Wednesday.

There are no approved vaccines for the illness caused by the new coronavirus, but 19 vaccines are being tested in humans around the world.

(Reporting by David Ljunggren; Editing by Andrew Heavens and Jonathan Oatis)

((; +1 613 235 6745; fax +1 613 235 5890; Reuters Messaging:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.